Metformin and its clinical use: New insights for an old drug in clinical practice

Archives of Medical Science

Volumn 8, Issue 5, 2012, Pages 907-917

  Cicero, Arrigo F G ^a   Tartagni, Elisa ^a   Ertek, Sibel ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UFUK UNIVERSITY   (Turkey)

Author keywords

Cancer; Efficacy; Metformin; Safety; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTILIPEMIC AGENT; CONTRAST MEDIUM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; LEPTIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SIBUTRAMINE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; VILDAGLIPTIN;

ABDOMINAL CRAMP; ANDROGEN BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TREATMENT FAILURE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOVOLEMIA; HYPOXIC RESPIRATORY DISEASE; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; LACTATION; LACTIC ACIDOSIS; LIVER PROTECTION; MACROSOMIA; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREECLAMPSIA; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREOPERATIVE PERIOD; RESPIRATORY TRACT DISEASE; REVIEW; RISK REDUCTION; SEPSIS; SIDE EFFECT; SYSTEMATIC REVIEW; VOMITING; WEIGHT GAIN;

EID: 84869750716     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.31622     Document Type: Review

References (131)

1. Goldman-Levine JD. Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus. Pharmacotherapy 2011; 31: 44S-53S.
2. Nathan DM, Buse JB, Davidson MB, Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A Consensus Statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-21. (Pubitemid 44025023)
3. Scarpello JHB. Optimal dosing strategies for modelling the clinical response to metformin in type 2 diabetes. Br J Diabetes Vasc Dis 2001; 1: 28-36.
4. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: result of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103: 491-7. (Pubitemid 28018651)
5. Fujioka K, Brazg RL, Raz I, et al. Efficacy, dose-response relationship and safety of once-daily extended release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes Metab 2005; 7: 28-39.
6. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin and placebo in dietary-treated NIDDM patients: the Essen-II study. Am J Med 1997; 103: 483-90. (Pubitemid 28018650)
7. Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 1637-45. (Pubitemid 36623381)
8. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N Eng J Med 2006; 335: 2427-43. (Pubitemid 44903747)
9. Derosa G, Maffioli P. Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther 2012; 14: 350-64.
10. Derosa G, Maffioli P. Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2011; 4: 263-71.
11. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl-peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-87. (Pubitemid 47219404)
12. Derosa G, Maffioli P, Salvadeo SA, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010; 59: 887-95.
13. Derosa G, Carbone A, Franzetti I, et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, beta-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 2012; doi: 10.1016/j.diabres.2012.05.022.
14. Schweizer A, Counturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-na?ve patients with type 2 diabetes. Diabet Med 2007; 24: 955-61. (Pubitemid 47301637)
15. Derosa G, Maffioli P, Ferrari I, et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res 2010; 42: 663-9.
16. Derosa G, Ragonesi PD, Carbone A, et al. Vildagliptin added to metformin on beta-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther 2012; 14: 475-484.
17. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 3: CD002966.
18. Hermann LS, Schersten B, Melander A. Antihyperglycemic efficacy, response prediction and dose response relations of treatment with metformin and sulfonylurea, alone and in primary combination. Diabet Med 1994; 11: 953-60. (Pubitemid 24375833)
19. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. The Multicenter Metformin Study Group. New Eng J Med 1995; 333: 541-9.
20. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001; 18: 828-34. (Pubitemid 32953790)
21. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002; 19: 673-80. (Pubitemid 34985169)
22. Goldstein BJ, Pans M, Rubin CJ. Multicenter, randomized, double masked parallel-group assessment of simultaneous glipizide/metformin as second line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther 2003; 25: 890-903. (Pubitemid 36459696)
23. Marre M, Van Gaal L, Usadel KH, Ball M, Whatmough I, Guitard C. Nateglinide improves glycemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab 2002; 4: 177-86. (Pubitemid 34567674)
24. Moses R. Repaglinide in combination therapy. Diabetes Nutr Metab 2002; 15: 33-8.
25. Philips R, Karrasch J, Scott R, Wilson D, Moses R. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003; 26: 269-73. (Pubitemid 36929042)
26. Chiasson JL, Naditch L, Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 2001; 24: 989-94. (Pubitemid 33716364)
27. Derosa G, Maffioli P. Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes. Diabetes Res Clin Pract 2011; 91: 265-70.
28. Derosa G, Maffioli P, Salvadeo SA, et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism 2009; 58: 1059-66.
29. Derosa G. Pioglitazone is a valid alternative to rosiglitazone. Am J Cardiovasc Drugs 2011; 11: 357-62.
30. Bailey CJ, Bagdonas A, Rubes J, et al. Rosiglitazone/ metformin fixed dose combination compared with uptitrated metformin alone n type 2 diabetes mellitus: a 24 week, multicenter, randomized, double-blind, parallel-group study. Clin Ther 2005; 27: 1548-61. (Pubitemid 41739491)
31. Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide vs metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obese Metab 2006; 8: 156-63.
32. Karamanos B, Thanopoulou A, Drossinos V, Charalampidou E, Sourmeli S, Archimandritis A; Hellenic ECLA Study Group. Study comparing the effect of pioglitazone in combination with either metformin or sulfonylureas. Curr Med Res Opin 2011; 27: 303-13.
33. Derosa G, D'Angelo A, Ragonesi PD, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J 2007; 37: 79-86. (Pubitemid 46066616)
34. Derosa G, D'angelo A, Ragonesi PD, et al. Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. J Int Med Res 2006; 34: 545-55.
35. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22: 1395-409. (Pubitemid 32056079)
36. Schweizer A, Coutrier A, Foley JA, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med 2007; 24: 955-61. (Pubitemid 47301637)
37. DeFronzo RA, Hissa MN, Garber AJ, et al; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care 2009; 32: 1649-55.
38. Derosa G, Maffioli P. GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. Curr Clin Pharmacol 2012; 7: 214-28.
39. Derosa G, Putignano P, Bossi AC, et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol 2011; 666: 251-6.
40. Derosa G, Franzetti IG, Querci F, et al. Exenatide plus metformin compared with metformin alone on beta-cell function in patients with type 2 diabetes. Diabet Med 2012; doi: 10.1111/j.1464-5491.2012.03699.x.
41. Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J; NN2211-1499 Study Group. Five-weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006; 114: 417-23. (Pubitemid 44620484)
42. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycemic control and weight in lower weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006; 8: 419-28. (Pubitemid 44349234)
43. Papanas N, Maltezos E. Metformin: a review of its use in the treatment of type 2 diabetes. Clin Med Therapeut 2009; 1: 1367-81.
44. Glueck CJ, Wang P, Kobayashi S, Philips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 520-5. (Pubitemid 34177206)
45. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17: 2858-64. (Pubitemid 35350902)
46. Checa MA, Requena A, Salvador C, et al; Reproductive Endocrinology Interest Group of the Spanish Society of Fertility. Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Hum Reprod Update 2005; 11: 375-90. (Pubitemid 40895466)
47. Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces preganancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Human Reprod 2004; 19: 1734-40. (Pubitemid 39144614)
48. Charles B, Norris R, Xiao X, Hague W. Population pharmacokinetics of metformin inlate pregnancy. Drug Monit 2006; 28: 67-72. (Pubitemid 44391696)
49. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Eng J Med 2008; 358: 2003-15. (Pubitemid 351656455)
50. Goh JE, Sadler L, Rowan J. Metformin for gestational diabetes in routine clinical practice. Diabet Med 2011; 28: 1082-7.
51. Nagai T, Imamura M, Mori M. Metformin use in an obese type 2 diabetic patient from weeks 1 to 21 of pregnancy. J Med 2003; 34: 163-8. (Pubitemid 47457283)
52. Hellmuth E, Damm P, Mo/lsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med 2000; 17: 507-11. (Pubitemid 30660151)
53. Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab 2010; 95: E448-55.
54. Glueck CJ, Wang P. Metformin before and during pregnancy and lactation in polycystic ovary syndrome. Expert Opin Drug Safety 2007; 6: 191-8. (Pubitemid 46380813)
55. Chatterjee R, Narayan KM, Limbscomb J, Philips LS. Screening adults for pre-diabetes and diabetes may be cost-saving. Diabetes Care 2010; 33: 1484-90.
56. Hopper I, Billah B, Skiba M, Krum H. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomized scontrolled trials. Eur J Cardiovasc Prev Rehab 2011; 18: 813-23.
57. Sullivan SD, Ratner ER. Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy? Curr Diab Rep 2011; 11: 91-8.
58. Sharma MD, Garber AJ. What is the best treatment for prediabetes? Curr Diab Rep 2009; 9: 335-41.
59. Lilly M, Godwin M. Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician 2009; 55: 363-9.
60. Nathan DM, Davidson MB, DeFronzo RA, et al; American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance. Diabetes Care 2007; 30: 753-9. (Pubitemid 46354366)
61. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-8. (Pubitemid 41071035)
62. Turner RC, Holman RR. Metformin and risk of cardiovascular disease. Cardiology 1999; 91: 203-4. (Pubitemid 29454259)
63. Sasali A, Leahy JL. Is metformin cardioprotective? Diabetes Care 2003; 26: 243-4. (Pubitemid 36929024)
64. Athyros VG, Ganotakis E, Kolovou GD, et al.; Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011; 9: 647-57.
65. Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother 2008; 42: 817-26. (Pubitemid 351778088)
66. Miller LJ. Management of atypical antipsychotic drug-induced weight gain: focus on metformin. Pharmacotherapy 2009; 29: 725-35.
67. Khan AY, Macaluso M, McHale RJ, Dahmen MM, Girrens K, Ali F. The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review. J Psychiatr Pract 2010; 16: 289-96.
68. Park MH, Kinra S, Ward KJ, White B, Viner RM. Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 2009; 32: 1743-5.
69. Yanovski JA, Krakoff J, Salaita CG, et al. Effects of metformin on body weight and body composition in obese, insulin-resistant children: a randomized clinical trial. Diabetes 2011; 60: 477-85.
70. Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002; 4: 49-55. (Pubitemid 34285267)
71. Sari R, Balci MK, Coban E, Yazicioglu G. Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. Int J Obes Relat Metab Disord 2004; 28: 1059-63. (Pubitemid 38998713)
72. Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab 2009; 11: 1091-9.
73. Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, Yovos JG, Karamitsos D. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Targets 2011; 15: 401-20.
74. Weickert MO, Hodges P, Tan BK, Randeva HS. Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin. Minerva Endocrinol 2012; 37: 25-40.
75. Alwis NMW, Day CP. Nonalcoholic fatty liver disease: the mistgradually clears. J Hepatol 2008; 48: S104-12.
76. Angulo P. Medical progress non-alcoholic fatty liver disease. N Eng J Med 2002; 346: 1221-31. (Pubitemid 34984585)
77. Sofer E, Boaz M, Matas Z, Mashavi M, Shargorodsky M. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with non-alcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism 2011; 60: 1278-84.
78. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res 2012; 2012: 716404.
79. Athyros VG, Tziomalos K, Gossios TD, et al.; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
80. Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011; 7: 796-805.
81. Huang Y, Fu JF, Shi HB, Liu LR. Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes. Zhonghua Er Ke Za Zhi 2011; 49: 139-45.
82. Wang CC, Kao JH. Metformin improves sustained virologic response in difficult-to-cure hepatitis C. More questions than answers. Hepatology 2010; 51: 1082-3.
83. Yilmaz Y, Yonal O, Imeryuz N. Metformin, hepatitis C, and insulin resistance: sufficient evidence? Hepatology 2009; 50: 2054-5.
84. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 2010; 162: 193-212.
85. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005; 106: 131-7. (Pubitemid 40898445)
86. Ercan EA, Ertek S, Is G, et al. Factors associated with increased carotid intima-media thickness and being non-dipper in non-obese and normotensive young patients affected by PCOS. Angiology 2011; 62: 543-8.
87. Genazzani AD, Ricchieri F, Lanzoni C. Use of metformin in the treatment of polycystic ovary syndrome. Women's Health 2010; 6: 577-93.
88. Geller DH, Pacaud D, Gordon CM, Misra M; Drug and Therapeutics Committee of the Pediatric Endocrine Society. State of the art review: emerging therapies: the use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS). Int J Pediatr Endocrinol 2011; 2011: 9-27.
89. Motta DA. Metformin in the treatment of polycystic ovary syndrome. Curr Pharm Res 2008; 14: 2121-5.
90. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin sensitizing drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligomenorrhea and subfertility. Cochrane Database Syst Rev 2009; 7: CD003053.
91. Duranteau L, Lefevre P, Jeandidier N, Simon T, Christin-Maitre S. Should physicians prescribe metformin to women with polycystic ovary syndrome (PCOS)? Ann Endocrinol 2010; 71: 25-7.
92. Tomova A, Deepinder F, Robeva R, Kirilov G, Mechandjiev Z, Kumanov P. Antimullerian hormone in women with polycystic ovary syndrome before and after therapy with metformin. Horm Metab Res 2011; 43: 723-7.
93. Katsiki N, Hatzitolios AI. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. Curr Opin Obstet Gynecol 2010; 22: 466-76.
94. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 2003; 35: 694-704. (Pubitemid 38058173)
95. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010; 60: 207-21.
96. Jonhson A, Pollak M. Insulin, glucose and increased risk of cancer in patients with type 2 diabetes. Diabetologia 2010; 53: 2086-8.
97. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15-25. (Pubitemid 43960587)
98. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: the metabolism and growth control in tumor suppression. Nat Rev Cancer 2009; 9: 563-75.
99. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804-12. (Pubitemid 350145909)
100. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB-1 tumor suppressor negatively regulates mTOR signalling. Cancer Cell 2004; 6: 91-9. (Pubitemid 38903165)
101. Engelman JA, Cantley LC. Chemoprevention meets glucose control. Cancer Prev Res 2010; 3: 1049-52.
102. Algire C, Moiseeva O, Deschênes-Simard X, et al. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res 2012; 5: 536-43.
103. Li W, Yuan Y, Huang L, Qiao M, Zhang Y. Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Res Clin Pract 2012; 96: 187-95.
104. Bao B, Wang Z, Ali S, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res 2012; 5: 355-64.
105. Kato K, Gong J, Iwama H, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vivo and in vitro. Mol Cancer Ther 2012; 11: 549-60.
106. Romero IL, McCormick A, McEwen KA, et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival and chemosensitivity. Obstet Gynecol 2012; 119: 61-7.
107. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER 2+ breast cancer. Ann Oncol 2012; 23: 1771-80.
108. Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011; 34: 2323-8.
109. Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2012; 109: 1495-502.
110. Wu N, Gu C, Gu H, Hu H, Han Y, Li Q. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma 2011; 58: 482-90.
111. Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD. Potent anti-proliferative effects of metformin on trastzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle 2011; 10: 2959-66.
112. Chen G, Xu S, Renko K, Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab 2012; 97: E510-20.
113. Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, et al. In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol 2011; 668: 373-82.
114. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012; 35: 299-304.
115. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 2012; 35: 119-24.
116. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 2010; 3: 1451-61.
117. Hanna RK, Zhou C, Malloy KM, et al. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of mTOR pathyway. Gynecol Oncol 2012; 125: 458-69.
118. Vakana E, Platanias LC. AMPK in BCR-ABL expressing leukemias: regulatory effects and therapeutic implications. Oncotarget 2011; 2: 1322-8.
119. Papanas N, Maltezos E, Mikhailidis DP. Metformin and cancer: licence to heal? Expert Opin Investig Drugs 2010; 19: 913-7.
120. Sharif A. Should metformin be our antiglycemic agent of choice post-transplantation? Am J Transplant 2011; 7: 1376-81.
121. Rezzónico J, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Related Disord 2011; 9: 69-75.
122. Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) 2010; 3: 1060-5.
123. Roche C, Nau A, Peytel E, Moalic JL, Oliver M. Severe lactic acidosis due to metformin: report of 3 cases. Ann Biol Clin (Paris) 2011; 69: 705-11.
124. Keller G, Cour M, Hernu R, Illinger J, Robert D, Argaud L. Management of metformin-associated lactic acidosis by continuous renal replacement therapy. PLos One 2011; 6: e23200.
125. Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 2011; 118: c380-3.
126. Papanas N, Maltezos E, Mikhailidis DP. Metformin and heart failure: never say never again. Expert Opin Pharmacother 2012; 13: 1-8.
127. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; 1: CD002967.
128. Kos E, Liszek MJ, Emanuele MA, Durazo-Arvizu R, Camacho P. The effect of metformin therapy on vitamin D and B12 levels in patients with diabetes mellitus type 2. Endocr Pract 2011; 22: 1-16.
129. Bell DS. Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. South Med J 2010; 103: 265-7.
130. Palomba S, Falbo A, Giallauria F, et al. Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care 2010; 33: 246-51.
131. Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley GP Jr. Association of biochemical B12 deficiency with metformin therapy and vitamin B12 supplements: the national health and nutrition examination survey, 1999-2006. Diabetes Care 2012; 35: 327-33.